首页> 外文期刊>Nature >Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
【24h】

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis

机译:癌基因诱导的Nrf2转录促进ROS解毒和肿瘤发生

获取原文
获取原文并翻译 | 示例
       

摘要

Reactive oxygen species (ROS) are mutagenic and may thereby promote cancer. Normally, ROS levels are tightly controlled by an inducible antioxidant program that responds to cellular stressors and is predominantly regulated by the transcription factor Nrf2 (also known as Nfe2l2) and its repressor protein Keap1 (refs 2-5). In contrast to the acute physiological regulation of Nrf2, in neopla-sia there is evidence for increased basal activation of Nrf2. Indeed, somatic mutations that disrupt the Nrf2-Keapl interaction to stabilize Nrf2 and increase the constitutive transcription of Nrf2 target genes were recently identified, indicating that enhanced ROS detoxification and additional Nrf2 functions may in fact be pro-tumorigenic. Here, we investigated ROS metabolism in primary murine cells following the expression of endogenous oncogenic alleles of Kras, Braf and Myc, and found that ROS are actively suppressed by these oncogenes. K-Ras~(G12D), B-Raf~(V619E) and Myc~(ERT2) each increased the transcription of Nrf2 to stably elevate the basal Nrf2 antioxidant program and thereby lower intracellular ROS and confer a more reduced intracellular environment. Oncogene-directed increased expression of Nrf2 is a new mechanism for the activation of the Nrf2 antioxidant program, and is evident in primary cells and tissues of mice expressing K-Ras~(G12D) and B-Raf~(V619E), and in human pancreatic cancer. Furthermore, genetic targeting of the Nrf2 pathway impairs K-Ras~(G12D)-induced proliferation and tumorigenesis in vivo. Thus, the Nrf2 antioxidant and cellular detoxification program represents a previously unappreciated mediator of oncogenesis.
机译:活性氧(ROS)具有致突变性,因此可能促进癌症。通常,ROS水平由可诱导抗氧化剂程序严格控制,该程序可对细胞应激物作出反应,并主要受转录因子Nrf2(也称为Nfe2l2)及其阻遏蛋白Keap1(参考文献2-5)的调节。与Nrf2的急性生理调节相反,在赘生物中,有证据表明Nrf2的基础激活增加。实际上,最近发现了破坏Nrf2-Keapl相互作用以稳定Nrf2并增加Nrf2靶基因组成型转录的体细胞突变,这表明增强的ROS解毒作用和其他Nrf2功能实际上可能是促肿瘤的。在这里,我们研究了Kras,Braf和Myc内源性致癌等位基因表达后原代小鼠细胞中的ROS代谢,发现ROS被这些癌基因积极抑制。 K-Ras〜(G12D),B-Raf〜(V619E)和Myc〜(ERT2)均增加Nrf2的转录,以稳定地提高基础Nrf2的抗氧化剂程序,从而降低细胞内ROS,并赋予细胞更加减少的细胞内环境。癌基因指导的Nrf2表达增加是激活Nrf2抗氧化剂程序的新机制,并且在表达K-Ras〜(G12D)和B-Raf〜(V619E)的小鼠的原代细胞和组织中以及在人类中很明显胰腺癌。此外,Nrf2途径的遗传靶向损害体内K-Ras〜(G12D)诱导的增殖和肿瘤发生。因此,Nrf2抗氧化剂和细胞排毒程序代表了以前未发现的肿瘤发生介质。

著录项

  • 来源
    《Nature》 |2011年第7354期|p.106-109|共4页
  • 作者单位

    Li Ka Shing Centre, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge CB2 ORE, UK,Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA;

    Li Ka Shing Centre, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge CB2 ORE, UK,University of Vienna, Dr. Bohrgasse 9,1030 Vienna, Austria;

    Li Ka Shing Centre, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge CB2 ORE, UK;

    Li Ka Shing Centre, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge CB2 ORE, UK,Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA;

    Center for Cancer Pharmacology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA;

    Li Ka Shing Centre, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge CB2 ORE, UK;

    Center for Cancer Pharmacology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA;

    Center for Cancer Pharmacology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA;

    Department of Surgery,Jefferson Medical College, Philadelphia, Pennsylvania 19107, USA;

    Department of Biology, Alma College, Alma, Michigan 48801, USA;

    Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, the Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA;

    Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, the Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA;

    Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, the Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA,Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, the Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA;

    Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, the Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA,Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, the Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA;

    Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, the Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA,Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, the Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA;

    Center for Cancer Pharmacology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA;

    Li Ka Shing Centre, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge CB2 ORE, UK;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 02:54:38

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号